Can paying attention to your body rewire your brain waves in 30 minutes?
NCT ID NCT07736365
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial tests whether a single, 30-minute guided body awareness session can alter brain wave patterns and improve the ability to sense one's own heartbeat. Healthy young adults aged 18-25 are randomly assigned to either the body awareness session or quiet rest. Brain activity is measured with a portable EEG, and heartbeat perception is tested before and after. The goal is to see if a brief mindfulness-like practice can produce measurable changes in the brain and body awareness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a single 30-minute session of Basic Body Awareness Therapy
- What this could lead to
- If it works, this could point toward simple, non-drug ways to improve mind-body awareness and mental well-being.
- What could go wrong
- This is a small, early-stage trial in healthy volunteers, so results may not apply to clinical populations. The effects of a single session may be subtle or short-lived.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 84 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 25 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-25 years * Self-reported healthy status * Literate in Turkish * Willing and able to provide written informed consent Exclusion Criteria: * Active epilepsy or seizure history * Diagnosed psychiatric disorder * Neurological disorder * Cardiac arrhythmia, pacemaker, heart disease * Active use of psychotropic, beta-blocker, anticholinergic, or antihistamine medication * Prior participation in Basic Body Awareness Therapy * Pregnancy * Active scalp lesion or dermatological pathology * Neurological/psychiatric medication affecting alertness or attention * Alcohol consumption in the last 24 hours * Excessive caffeine intake on the day of measurement * Acute pain, fever, infection, or other condition that could affect measurement
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers - male and female are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New lung imaging technique uses inhaled gas to see inside your lungs
- Quinoa cookie trial: a tasty way to fight obesity?
- New RNA drug ORN252 tested in humans for first time
- Scientists test drug binding in healthy lungs to guide future treatments
- New drug QLS7305 tested in healthy volunteers – first step for future therapies
- New antibody drug aims to regrow hair – first human trial underway